Tenaya Therapeutics focuses its research and development pipeline on addressing severe genetic and acquired forms of heart disease, primarily cardiomyopathies that can lead to heart failure. Key disease targets include MYBPC3-associated hypertrophic cardiomyopathy addressed by its lead gene therapy candidate TN-201, PKP2-associated arrhythmogenic right ventricular cardiomyopathy targeted by TN-401, and prevalent forms of heart failure with preserved ejection fraction addressed by its precision small-molecule program TN-301.